| Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer CN Catton, H Lukka, CS Gu, JM Martin, S Supiot, PWM Chung, ... Journal of Clinical Oncology 35 (17), 1884-1890, 2017 | 703 | 2017 |
| Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label … K Fizazi, S Foulon, J Carles, G Roubaud, R McDermott, A Fléchon, ... The Lancet 399 (10336), 1695-1707, 2022 | 521 | 2022 |
| Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised … C Carrie, A Hasbini, G de Laroche, P Richaud, S Guerif, I Latorzeff, ... The Lancet Oncology 17 (6), 747-756, 2016 | 416 | 2016 |
| Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG … P Sargos, S Chabaud, I Latorzeff, N Magné, A Benyoucef, S Supiot, ... The Lancet Oncology 21 (10), 1341-1352, 2020 | 266 | 2020 |
| Cancer radioimmunotherapy with alpha-emitting nuclides O Couturier, S Supiot, M Degraef-Mougin, A Faivre-Chauvet, T Carlier, ... European journal of nuclear medicine and molecular imaging 32, 601-614, 2005 | 231 | 2005 |
| Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of … C Carrie, N Magné, P Burban-Provost, P Sargos, I Latorzeff, JL Lagrange, ... The Lancet Oncology 20 (12), 1740-1749, 2019 | 221 | 2019 |
| Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity A Choudhury, H Zhao, F Jalali, S Al Rashid, J Ran, S Supiot, AE Kiltie, ... Molecular cancer therapeutics 8 (1), 203-213, 2009 | 124 | 2009 |
| Daily versus weekly prostate cancer image guided radiation therapy: phase 3 multicenter randomized trial R de Crevoisier, MA Bayar, P Pommier, X Muracciole, F Pêne, P Dudouet, ... International Journal of Radiation Oncology* Biology* Physics 102 (5), 1420-1429, 2018 | 118 | 2018 |
| A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity N Alvarez-Rueda, A Desselle, D Cochonneau, T Chaumette, ... PloS one 6 (9), e25220, 2011 | 107 | 2011 |
| The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy O Guipaud, C Jaillet, K Clément-Colmou, A François, S Supiot, F Milliat The British journal of radiology 91 (1089), 20170762, 2018 | 97 | 2018 |
| Comparison of automated atlas-based segmentation software for postoperative prostate cancer radiotherapy G Delpon, A Escande, T Ruef, J Darréon, J Fontaine, C Noblet, S Supiot, ... Frontiers in oncology 6, 178, 2016 | 96 | 2016 |
| LBA5 A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: overall survival with abiraterone acetate plus … K Fizazi, JC Galceran, S Foulon, G Roubaud, R McDermott, A Fléchon, ... Annals of Oncology 32, S1299, 2021 | 92 | 2021 |
| Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53 S Supiot, RP Hill, RG Bristow Molecular cancer therapeutics 7 (4), 993-999, 2008 | 86 | 2008 |
| Improved functionality of the vasculature during conventionally fractionated radiation therapy of prostate cancer VA Potiron, R Abderrahmani, K Clément-Colmou, S Marionneau-Lambot, ... PloS one 8 (12), e84076, 2013 | 85 | 2013 |
| Interstitial brachytherapy of periorificial skin carcinomas of the face: a retrospective study of 97 cases E Rio, E Bardet, C Ferron, P Peuvrel, S Supiot, L Campion, ... International Journal of Radiation Oncology* Biology* physics 63 (3), 753-757, 2005 | 79 | 2005 |
| Videotaped simulated interviews to improve medical students' skills in disclosing a diagnosis of cancer A Bonnaud‐Antignac, L Campion, P Pottier, S Supiot Psycho‐Oncology 19 (9), 975-981, 2010 | 73 | 2010 |
| Comparison of the biologic effects of MA5 and B‐B4 monoclonal antibody labeled with iodine‐131 and bismuth‐213 on multiple myeloma S Supiot, A Faivre‐Chauvet, O Couturier, MF Heymann, N Robillard, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2002 | 73 | 2002 |
| Mechanisms of cell sensitization to α radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines S Supiot, S Gouard, J Charrier, C Apostolidis, JF Chatal, J Barbet, ... Clinical cancer research 11 (19), 7047s-7052s, 2005 | 67 | 2005 |
| OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer S Supiot, L Vaugier, D Pasquier, X Buthaud, N Magné, D Peiffert, ... European Urology 80 (4), 405-414, 2021 | 65 | 2021 |
| Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions VA Potiron, R Abderrhamani, E Giang, S Chiavassa, E Di Tomaso, ... Radiotherapy and Oncology 106 (1), 138-146, 2013 | 63 | 2013 |
Sophie ChiavassaICO Nantes - CNRS SUBATECH PRISMAVerified email at ico.unicancer.fr
